# Shaanxi Investment Capital

> Shaanxi Investment Capital is a VC fund in Xian backing Manufacturing and Biotechnology. See 20 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Xian, China
- Total investments: 20
- Last investment: Jun 2025
- Lead investor: 30%
- Last updated: Aug 2026
- Website: http://www.sxstzb.com/

Shaanxi Investment Capital is a VC fund in Xian focused on Manufacturing and Biotechnology. Shaanxi Investment Growth Fund is an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Manufacturing | 6 | 30% |
| Biotechnology | 5 | 25% |
| Medical | 4 | 20% |
| Advanced Materials | 3 | 15% |
| Biopharma | 2 | 10% |

29 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 30% |
| Seed | 5 | 25% |
| Series A | 5 | 25% |
| Series C | 1 | 5% |
| Venture - Series Unknown | 1 | 5% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Zhonghui Medicine | Zhonghui Medicine is the first hollow microneedle research and development and production company in China with independent intellectual property rights. | $7M | Seed | Jun 09, 2025 |  |
| Jingwei New Materials | Jingwei New Materials is a copper alloy material manufacturer that makes copper-based and associated auxiliary new materials. |  | Seed | Jun 12, 2024 |  |
| Bio Regenmed | Bioregeneration is a national high-tech industrial firm that creates and manufactures innovative biomedical materials with the goal of human tissue engineering and organ repair. |  | Series C | Dec 28, 2023 |  |
| Neurodome | Neurodome is a manufacturer of non-invasive deep brain nerve modulation technology. It focuses on the research and development of non-invasive deep brain nerve modulation products. |  | Seed | Dec 27, 2023 |  |
| Rongcan Bio | Rongcan Bio completes the nucleic acid industry chain from nucleic acid sequence design, mRNA nucleic acid raw material synthesis, delivery carrier synthesis, and final drug delivery. It is a nucleic acid drug development and industrialization service provider. | $14M | Series A | Dec 06, 2023 |  |
| GeneRulor | GeneRulor is a biomedical company that offers molecular diagnostics and gene editing technology services for viral infections and related tumor diseases. |  | Series A | Sep 05, 2023 |  |
| Solidarity | Solid New Materials is a high-energy density battery core material developer. |  | Seed | Jun 01, 2023 |  |
| Zhilun Ultra-Pure | Zhilun Ultra-Pure is a high-tech firm that combines high-quality resources, works autonomously, and is distinguished by "specialization, precision, and special innovation" by three technology-based new material companies. It is dedicated to ultra-high-purity electronic-grade epoxy. The Electronic Chemical New Material IndustryAlliance's governing unit is R&D and production and sales resin. |  | Seed | May 22, 2023 |  |
| Blueray Med | Blueray Med medical device enterprise focusing on a new generation of optomechanical computing. It has established a 2000M² GMP standard production base in Caotang Industrial Park, Xi'an High-tech Zone. The world's first blue laser laser surgery system has been developed, which will be used for the operation of superficial diseases in thecavity and the surgical treatment of other diseases in urology. The product line includes high, medium and low power blue laser surgical systems and consumables. The world's first blue laser surgery system has been granted the Class III registration certificate issued by the State Drug Administration on November 16, 2021, and the world's most powerful 200W blue laser surgery system has been granted the National Drug Administration on April 6, 2022 Three types of registration certificates issued by the Authority. The company will begin to obtain EU CE product certification in 2023, providing cost-effective, safe and effective medical devices for domestic and foreign hospitals. |  | Series A | Apr 12, 2023 |  |
| Blueray Med | Blueray Med medical device enterprise focusing on a new generation of optomechanical computing. It has established a 2000M² GMP standard production base in Caotang Industrial Park, Xi'an High-tech Zone. The world's first blue laser laser surgery system has been developed, which will be used for the operation of superficial diseases in thecavity and the surgical treatment of other diseases in urology. The product line includes high, medium and low power blue laser surgical systems and consumables. The world's first blue laser surgery system has been granted the Class III registration certificate issued by the State Drug Administration on November 16, 2021, and the world's most powerful 200W blue laser surgery system has been granted the National Drug Administration on April 6, 2022 Three types of registration certificates issued by the Authority. The company will begin to obtain EU CE product certification in 2023, providing cost-effective, safe and effective medical devices for domestic and foreign hospitals. |  | Series A | Apr 12, 2023 |  |

10 of 20 investments shown.

## Co-investors
- Shaanxi Investment Growth Fund — VC Fund, 4 deals together
- [CAS Star](https://shizune.co/investors/profile/cas-star) — VC Fund, 2 deals together
- [Guangzhou Yuexiu Industrial Investment Fund](https://shizune.co/investors/profile/guangzhou-yuexiu-industrial-investment-fund) — VC Fund, 2 deals together
- Hefei Zhonghe Opple Medical and Health Industry fund — VC Fund, 2 deals together
- [Xi'an Caijin](https://shizune.co/investors/profile/xi-an-caijin-c7fc) — VC Fund, 2 deals together
- [Addor Capital](https://shizune.co/investors/profile/addor-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Shaanxi Investment Capital invest in?

Shaanxi Investment Capital invests primarily in Manufacturing, Biotechnology and Medical startups, most often at Series B and Seed stage. Most of the 20 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Shaanxi Investment Capital last invest?

The most recent investment recorded for Shaanxi Investment Capital closed in Jun 2025. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co